Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema

Trial ID or NCT#

NCT01893879

Status

not recruiting iconNOT RECRUITING

Purpose

This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.

Official Title

Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Axillary lymph node dissection within the preceding 12 months
Exclusion Criteria:
  1. - Patients with active cancer - Patients with lymphedema - Infection or bleeding tendency - Patients with medical contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs), including history of allergies, know gastrointestinal intolerance - Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate - Persons not competent to consent - Patients on aspirin therapy - Minors (< 18 years of age) - Pregnant and/or lactating women - Males
View All Criteria
Show Less

Investigator(s)

Stanley G. Rockson, MD
Stanley G. Rockson, MD
Cardiologist
Allan and Tina Neill Professor of Lymphatic Research and Medicine

View on ClinicalTrials.gov